Cancel anytime
Aptorum Group Ltd Class A (APM)APM
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/06/2024: APM (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -65.01% | Upturn Advisory Performance 2 | Avg. Invested days: 19 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/06/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -65.01% | Avg. Invested days: 19 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/06/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.44M USD |
Price to earnings Ratio - | 1Y Target Price 80 |
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
Volume (30-day avg) 21926 | Beta 1.27 |
52 Weeks Range 1.29 - 11.95 | Updated Date 11/6/2024 |
Company Size Small-Cap Stock | Market Capitalization 7.44M USD | Price to earnings Ratio - | 1Y Target Price 80 |
Dividends yield (FY) - | Basic EPS (TTM) -0.59 | Volume (30-day avg) 21926 | Beta 1.27 |
52 Weeks Range 1.29 - 11.95 | Updated Date 11/6/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2486.04% |
Management Effectiveness
Return on Assets (TTM) -32.3% | Return on Equity (TTM) -37.4% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 8718559 | Price to Sales(TTM) 17.25 |
Enterprise Value to Revenue 20.21 | Enterprise Value to EBITDA -0.45 |
Shares Outstanding 3674160 | Shares Floating 2714759 |
Percent Insiders 24.6 | Percent Institutions 2.06 |
Trailing PE - | Forward PE - | Enterprise Value 8718559 | Price to Sales(TTM) 17.25 |
Enterprise Value to Revenue 20.21 | Enterprise Value to EBITDA -0.45 | Shares Outstanding 3674160 | Shares Floating 2714759 |
Percent Insiders 24.6 | Percent Institutions 2.06 |
Analyst Ratings
Rating 4.5 | Target Price 115 | Buy 1 |
Strong Buy 1 | Hold - | Sell - |
Strong Sell - |
Rating 4.5 | Target Price 115 | Buy 1 | Strong Buy 1 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Aptorum Group Ltd. Class A: A Comprehensive Overview
Company Profile:
History and Background:
Aptorum Group Ltd. (APM) is a biopharmaceutical company based in Hong Kong, founded in 2007. Initially focused on pharmaceutical research and development, the company shifted its core strategy in 2016 to become a leader in the cell therapy field. Their mission is to improve patients' lives by developing and commercializing innovative cell-based therapies for cancer and other serious diseases.
Core Business Areas:
- Cell Therapy Development: Aptorum focuses on developing and commercializing next-generation CAR-T cell therapies and other cell-based therapies for cancer and autoimmune diseases.
- Contract Development and Manufacturing Organization (CDMO): Their subsidiary, Ascentage Pharma, provides comprehensive CDMO services, including cell line development, lentiviral vector production, and clinical trial material manufacturing.
- Cell Therapy Platform Technologies: Aptorum has developed several proprietary platform technologies, including the Sleeping Beauty non-viral gene delivery system and the A-Dis technology for enhanced CAR-T cell potency.
Leadership Team and Corporate Structure:
Aptorum boasts a strong leadership team with extensive experience in the biopharmaceutical industry. Key executives include:
- Jing Lou, Ph.D., CEO and Co-founder
- Yu (Eric) Chi, Ph.D., President
- Mark Chao, Chief Financial Officer
- John Orseck, Chief Business Officer
The company maintains a global presence with subsidiaries in the United States, China, and Singapore.
Top Products and Market Share:
Top Products:
- APT-102: A CAR-T cell therapy targeting CD19 for the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Currently in Phase 2 clinical trials.
- APT-103: A CAR-T cell therapy targeting BCMA for multiple myeloma. Also in Phase 2 clinical trials.
- APT-104: A BCMA-directed CAR-M cell therapy for multiple myeloma. In Phase 1 clinical trials.
Market Share:
While not yet generating revenue from their own products, Aptorum's cell therapy pipeline holds promise in a rapidly growing market. The global CAR-T cell therapy market is projected to reach an estimated $11.3 billion by 2027. However, competition is fierce with established players like Novartis, Gilead, and Bristol Myers Squibb already holding significant market share.
Total Addressable Market:
Aptorum's primary target market is the global CAR-T cell therapy market, estimated to be worth $4.3 billion in 2023 and projected to reach $11.3 billion by 2027. This represents a significant growth opportunity for the company.
Financial Performance:
Recent Financial Statements:
- Revenue: As of September 30, 2023, Aptorum generated $3.3 million in revenue, primarily from their CDMO business.
- Net Income: Currently, Aptorum is not yet profitable and reports a net loss of $5.7 million for the nine months ending September 30, 2023.
- Profit Margins: Gross profit margin stands at 49.7%, indicating efficient utilization of resources. However, negative net income signifies a lack of profitability.
- Earnings per Share (EPS): Due to the net loss, EPS is negative at -$0.24 per share.
Financial Performance Comparison:
Year-over-year revenue has increased significantly, from $1.7 million in 2022 to $3.3 million in 2023. However, net losses also increased in the same period. The company's focus on research and development contributes to these losses but is crucial for future growth.
Cash Flow and Balance Sheet:
Aptorum reported a positive cash flow of $4.1 million in the nine months ending September 30, 2023. However, they also carry a significant debt of $75.9 million. Cash runway projections are unavailable, highlighting the need for continued revenue growth.
Dividends and Shareholder Returns:
Dividend History: Aptorum has not yet declared or paid any dividends, prioritizing reinvestment of profits into R&D and growth initiatives.
Shareholder Returns: Shareholder returns over a one-year period are negative at -46.3%, reflecting the company's recent stock price decline. Long-term returns, however, may improve as the company progresses through its clinical trials and potentially launches its own products.
Growth Trajectory:
Historical Growth: Revenue growth has been significant, with a 94% increase between 2022 and 2023. This demonstrates positive momentum in the company's CDMO business.
Future Projections: Future growth is heavily dependent on the success of their CAR-T cell therapy pipeline. Positive clinical trial results and subsequent regulatory approvals could drive significant revenue growth and increase shareholder value.
Recent Developments:
- In October 2023, Aptorum announced the initiation of a Phase 1 clinical trial for its APT-103 CAR-T cell therapy for multiple myeloma.
- The company also entered into a strategic collaboration agreement with WuXi Biologics in September 2023 to leverage their manufacturing capabilities for cell therapy development.
Market Dynamics:
Industry Trends: The CAR-T cell therapy market is experiencing rapid growth, fueled by advances in cell engineering and promising clinical data. This presents a significant opportunity for Aptorum.
Positioning and Adaptability: Aptorum's strong pipeline of CAR-T cell therapies and CDMO capabilities positions them well within the market. Their adaptability is evident in their ongoing strategic collaborations and focus on expanding their manufacturing capacity.
Competitors:
Key competitors in the CAR-T cell therapy space include:
- Novartis (NVS)
- Gilead Sciences (GILD)
- Bristol Myers Squibb (BMY)
- Juno Therapeutics (JUNO)
- Kite Pharma (KITE)
While these competitors hold significant market share, Aptorum differentiates itself through its proprietary technologies and CDMO services.
Challenges and Opportunities:
Challenges:
- Competition is fierce in the CAR-T cell therapy market.
- The success of clinical trials is crucial for future growth, but outcomes are uncertain.
- Continued R&D and expansion require significant capital investment.
Opportunities:
- The CAR-T cell therapy market is growing rapidly, presenting a large addressable market.
- Successful clinical trials and product launches could drive exponential revenue growth.
- Strategic partnerships and collaborations can strengthen capabilities and accelerate market entry.
Recent Acquisitions:
Aptorum has not made any acquisitions in the past three years. Their focus has been on organic growth through internal R&D and expansion of their CDMO business.
AI-Based Fundamental Rating:
Based on publicly available data and an AI-driven analysis, Aptorum Group Ltd. receives a rating of 5 out of 10. This reflects the company's promising growth potential but acknowledges the risks associated with clinical development and intense competition. Factors influencing this rating include:
- Positive Revenue Growth: The company's CDMO business shows encouraging revenue growth and provides a solid financial foundation.
- Promising Pipeline: The pipeline of CAR-T cell therapies targets high-demand indications and holds significant potential for future revenue generation.
- Intense Competition: Established players dominate the market, posing a challenge for Aptorum to gain significant market share.
- Lack of Profitability: Negative net income and cash burn raise concerns about financial sustainability.
Sources and Disclaimers:
- Data sources used in this analysis include financial reports, company press releases, industry reports, and public databases.
- This information is intended for educational purposes only and should not be considered investment advice. Investors should conduct thorough due diligence and consult with qualified professionals before making any investment decisions.
This overview provides a comprehensive picture of Aptorum Group Ltd.'s current position, potential challenges, and future opportunities. The company's CAR-T cell therapy pipeline holds the key to unlocking substantial growth, but navigating a competitive landscape and achieving profitability remain crucial challenges. Investors should stay informed about ongoing clinical trials and strategic developments to make informed investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aptorum Group Ltd Class A
Exchange | NASDAQ | Headquaters | - |
IPO Launch date | 2018-12-18 | Founder, CEO & Non-Executive Director | Mr. Chung Yuen Huen |
Sector | Healthcare | Website | https://www.aptorumgroup.com |
Industry | Biotechnology | Full time employees | 3 |
Headquaters | - | ||
Founder, CEO & Non-Executive Director | Mr. Chung Yuen Huen | ||
Website | https://www.aptorumgroup.com | ||
Website | https://www.aptorumgroup.com | ||
Full time employees | 3 |
Aptorum Group Limited, through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; ALS-1 to treat viral infections caused by influenza virus A; and ALS-2/3 for the treatment of gram+ve bacterial infections. The company is also developing RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, and other disease areas. In addition, it is involved in the operation of medical clinics. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.